Skip to content

New tumor marker for early detection of hepatocellular carcinoma (HCC)

New tumor marker for early detection of hepatocellular carcinoma (HCC)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200313001
Enrollment
1080
Registered
2020-03-13
Start date
2020-03-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apply to basic benefits in screening people at high risk of liver cell cancer at the national level PIVKA&#45

Interventions

1.Annual health check&#45
ups that have normal blood tests&#44
including high&#45
frequency ultrasound&#44
do not have a lump suspected of primary liver cancer 2.Patients with hepatitis B virus infection Hepatitis C And cirrhosis patients from various causes 3.Patients who have detected a lump in the liver
ray of the upper abdomen.
Treatment
Patients whom had risks for HCC

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and older 2. The annual health check-up who has regular blood tests including high frequency sound tests and no lumps suspected of primary liver cancer 3. Chronic hepatitis B patients Males aged over 40 years and females aged over 50 or have direct relatives with primary liver cancer 4.Chronic hepatitis C patients with pathological effects of liver tissue With at least level 3 fascia Or the flexibility of the liver with transient elastography greater than or equal to 9.5 or blood Fibrotest® is greater than 0.58 regardless of whether it has been treated or not. 5. Patients who have been diagnosed with liver cirrhosis for any reason From the examination of high frequency sound waves Radiographic images using a computer or an X-ray of the upper abdomen. 6. Patients who have detected a lump in the liver greater than or equal to 1 cm in size from the ultrasound Radiographic images using a computer or an X-ray of the upper abdomen.

Exclusion criteria

Exclusion criteria: 1. pregnant patients 2. Patients with jaundice from biliary tract obstruction 3. Patients who received vitamin K during the study 4. Patients receiving warfarin While studying 5. Other types of cancer detected While diagnosing primary liver cancer

Design outcomes

Primary

MeasureTime frame
Primary liver cancer diagnosis 3 year PIVKA-II Test µTASWako i30, ELECSYS, ARCHITECT AFP-L3

Secondary

MeasureTime frame
N/A N/A N/A

Countries

Thailand

Contacts

Public ContactWattana Sukeepaisarnjaroen

Khonkaen University

wattanasukee@gmail.com0873731133

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026